KAS
RVMD icon

Kemnay Advisory Services’s Revolution Medicines RVMD Stock Holding History

Kemnay Advisory Services’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
85
+10
+13% +$1.46K ﹤0.01% 873
2026
Q1 		$7.29K Buy
+75
New +$7.57K ﹤0.01% 1081

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Kemnay Advisory Services's RVMD Position: Q2 2026 in Review

Kemnay Advisory Services increased its Revolution Medicines (RVMD) stake by 13% in Q2 2026, buying an estimated $1.46K and bringing the position to 85 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Kemnay Advisory Services first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Kemnay Advisory Services held 85 shares of Revolution Medicines worth $15.9K as of Q2 2026.
  • Kemnay Advisory Services bought 10 Revolution Medicines shares in Q2 2026, an estimated $1.46K.
  • Revolution Medicines made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #873 holding.
  • Kemnay Advisory Services first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.